WHAT IS CLAIMED IS

- 1. A peptide composition of less than 500 amino acid residues comprising a peptide epitope useful for inducing an immune response against MAGE2/3 said epitope (a) having an amino acid sequence of about 8 to about 13 amino acid residues that have at least 65% identity with a native amino acid sequence of MAGE2/3 and, (b) binding to at least one HLA class I allele with an IC₅₀ of less than about 500 nM.
- 2. The composition of claim 1, further wherein said peptide has at least 77% identity with a native MAGE2/3 amino acid sequence.
- 3. The composition of claim 1, further wherein said peptide has 100% identity with a native MAGE2/3 amino acid sequence.
- 4. A pharmaceutical composition comprising a peptide and a pharmaceutical carrier, wherein the peptide is a peptide of Table VII (A1 supermotif), Table VIII (A2 supermotif/A*0201 motif), Table IX (A3 supermotif), Table X (A24 supermotif), Table XI (B7 supermotif), Table XII (B27 supermotif), Table XIII (B58 supermotif), Table XIV (B62 supermotif), Table XV (A1 motif), Table XVI (A3 motif), Table XVII (A11 motif), or Table XVIII (A24 motif) comprising an IC₅₀ of less than about 500 nM for at least one HLA class I molecule.
- 5. The pharmaceutical composition of claim 4 wherein the composition comprises the peptide in a form of nucleic acids that encode the peptide.
- 6. The pharmaceutical composition of claim 5 wherein the composition comprises the peptide in a form of nucleic acids that encode the epitope and one or more additional peptide(s).
- 7. The composition of claim 4, wherein the peptide is comprised by a longer peptide, with a *proviso* that the longer peptide is not an entire native antigen.
- 8. The pharmaceutical composition of claim 4 wherein the peptide is in a human dose form, and the carrier is in a human unit dose.

- 9. A peptide composition of claim 1 comprising an analog of a peptide epitope, wherein the peptide epitope is an epitope of Table VII (A1 supermotif), Table VIII (A2 supermotif/A2.1 motif), Table IX (A3 supermotif), Table X (A24 supermotif), Table XI (B7 supermotif), Table XII (B27 supermotif), Table XIII (B58 supermotif), Table XIV (B62 supermotif), Table XV (A1 motif), Table XVI (A3 motif), Table XVII (A11 motif), or Table XVIII (A24 motif), said analog comprising a preferred or less preferred amino acid of Table II substituted in for a starting residue, or having a deleterious residue of Table II substituted out of the starting sequence and replaced by a non-deleterious residue.
- 10. A peptide composition of claim 9 comprising a peptide of Table XXII.
- 11. A method for inducing a cytotoxic T lymphocyte response, said method comprising steps of:

providing a peptide that comprises an IC₅₀ of less than about 500 nM for an HLA class I molecule, wherein the peptide is a peptide of Table VII (A1 supermotif), Table VIII (A2 supermotif/A2.1 motif), Table IX (A3 supermotif), Table X (A24 supermotif), Table XI (B7 supermotif), Table XII (B27 supermotif), Table XIII (B58 supermotif), Table XIV (B62 supermotif), Table XV (A1 motif), Table XVI (A3 motif), Table XVII (A11 motif), Table XVIII (A24 motif), or Table XXII; and,

administering said peptide to a human.

- 12. The method of claim 11, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide.
- 13. The method of claim 12, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide and at least one additional peptide, with a *proviso* that an additional peptide is not an entire native antigen.
- 14. The method of claim 11, wherein the providing step provides the peptide comprised by a longer peptide, with a *proviso* that the longer peptide is not an entire native antigen.

15. A method for inducing a cytotoxic T lymphocyte response, said method comprising steps of:

providing a pharamceutical composition comprising a peptide and a pharmaceutical carrier, wherein the peptide induces a cytotoxic T cell response *in vitro* and/or *in vivo*, and further wherein the peptide is a peptide of Table VII (A1 supermotif), Table VIII (A2 supermotif/A2.1 motif), Table IX (A3 supermotif), Table X (A24 supermotif), Table XI (B7 supermotif), Table XII (B27 supermotif), Table XIII (B58 supermotif), Table XIV (B62 supermotif), Table XV (A1 motif), Table XVI (A3 motif), Table XVII (A11 motif), Table XVIII (A24 motif), or Table XXIII; and,

administering said pharmaceutical composition to a human.

- 16. The method of claim 15, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide.
- 17. The method of claim 16, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide and at least one additional peptide, with a *proviso* that an additional peptide is not an entire native antigen.
- 18. The method of claim 15, wherein the providing step provides the peptide comprised by a longer peptide, with a *proviso* that the longer peptide is not an entire native antigen.
- 19. The method of claim 15, wherein the providing step comprises a peptide that induces a cytotoxic T cell response when complexed with an HLA class I molecule and is presented to an HLA class I-restricted cytotoxic T cell.
- 20. A peptide composition of less than 500 amino acid residues comprising a peptide epitope useful for inducing an immune response against MAGE2/3 said epitope (a) having an amino acid sequence of about 6 to about 25 amino acid residues that have at least 65% identity with a native amino acid sequence of MAGE2/3 and, (b) binding to at least one HLA class II HLA allele with an IC₅₀ of less than about 1000 nM.

- 21. The peptide composition of claim 20, further wherein said peptide has at least 77% identity with a native MAGE2/3 amino acid sequence.
- 22. The peptide composition of claim 20, further wherein said peptide has 100% identity with a native MAGE2/3 amino acid sequence.
 - 23. A pharmaceutical composition comprising:

a human dose form of a peptide of Table XIX or Table XX that comprises an IC₅₀ of less than about 1,000 nM for at least one HLA DR molecule of an HLA DR supertype; and,

a human dose of a pharmaceutically acceptable carrier.

- 24. The pharmaceutical composition of claim 23 wherein the composition comprises the peptide in a form of nucleic acids that encode the peptide.
- 25. The pharmaceutical composition of claim 24 wherein the composition comprises the peptide in a form of nucleic acids that encode the peptide and at least one additional peptide, with a *proviso* that an additional peptide is not an entire native antigen.
- 26. The pharmaceutical composition of claim 25, wherein the peptide is comprised by a longer peptide, with a *proviso* that the longer peptide is not an entire native antigen.
- 27. A peptide composition of claim 20 comprising an analog of a peptide epitope of Table XIX or Table XX, said analog comprising a preferred or less preferred amino acid of Table III substituted in for a starting residue, and/or having a deleterious residue of Table III substituted out of the starting sequence and replaced by a non-deleterious residue.

28. A method for inducing a helper T lymphocyte response, said method comprising steps of:

providing a pharmaceutical composition comprising a human dose of a peptide that comprises an IC₅₀ of less than about 1,000 nM for an HLA class II molecule and a human dose of a pharmaceutical carrier, wherein the peptide is a peptide of Table XIX or Table XX; and,


administering said peptide to a human.

- 29. The method of claim 28, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide.
- 30. The method of claim 29, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide and at least one additional peptide, with a *proviso* that an additional peptide is not an entire native antigen.
- 31. The method of claim 28, wherein the providing step provides the peptide comprised by a longer peptide, with a *proviso* that the longer peptide is not an entire native antigen.
- 32. A method for inducing a helper T lymphocyte response, said method comprising steps of:

providing a pharmaceutical composition comprising a human dose of a peptide that induces a helper T cell response *in vitro* and/or *in vivo* and a pharmaceutically acceptable carrier, wherein the peptide is a peptide of Table XIX or Table XX; and,

administering said pharmaceutical composition to a human.

- 33. The method of claim 32, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide.
- 34. The method of claim 33, wherein the providing step provides the peptide in a form of nucleic acids that encode the peptide and at least one additional peptide, with a *proviso* that an additional peptide is not an entire native antigen.



- 36. The method of claim 32, wherein the providing step comprises a peptide that induces a helper T cell response when complexed with an HLA class II molecule and is presented to an HLA class II-restricted helper T cell.
- 37. A vaccine for preventing or treating cancer that induces a protective or therapeutic immune response, wherein said vaccine comprises: at least one peptide selected from Table(s) VII-XX or Table XXII; and, a pharmaceutically acceptable carrier.
- 38. A kit for a vaccine that induces a protective or therapeutic immune response to a tumor, said vaccine comprising:

at least one peptide selected from Table(s) VII-XX or Table XXII; a pharmaceutically acceptable carrier; and, instructions for administration to a patient.

39. A method for monitoring or evaluating an immune response to a tumor or an epitope thereof in a patient having a known HLA type, the method comprising:

incubating a T lymphocyte sample from the patient with a peptide selected from Table(s) VII-XX or Table XXII, wherein that peptide bears a motif corresponding to at least one HLA allele present in said patient; and,

detecting the presence of a T lymphocyte that recognizes the peptide.

40. The method of claim 39, wherein the peptide is comprised by a tetrameric complex.